EYP001A clinical trials
Also written EYP001a.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses EYP001A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- EYP001a
- 6
Studies by the year they started
6 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Enyo Pharma (6)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses EYP001A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)TerminatedPhase 2Enyo PharmaNCT04465916Written as EYP001a
- A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With EntecavirCompletedPhase 2Enyo PharmaNCT04365933Written as EYP001a
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis PatientsCompletedPhase 1Enyo PharmaNCT03976687Written as EYP001a
- Evaluation of the Safety and Pharmacology of EYP001 in HBV SubjectsCompletedPhase 1Enyo PharmaNCT03272009Written as EYP001a
- EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) InfectionCompletedPhase 1Enyo PharmaNCT03320616Written as EYP001a
- Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male SubjectsCompletedPhase 1Enyo PharmaNCT03110276Written as EYP001a